Exendin-4 reverses biochemical and behavioral deficits in a pre-motor rodent model of Parkinson's disease with combined noradrenergic and serotonergic lesions

Neuropeptides

Volumn 46, Issue 5, 2012, Pages 183-193

  Rampersaud, N ^a   Harkavyi, A ^a   Giordano, G ^a   Lever, R ^a   Whitton, J ^a   Whitton, P S ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

6 OHDA; DSP 4; EX 4; Exendin 4; Force swim test; FST; GLP 1; NOR; Novel object recognition; OFT; Parachloroamphetamine; Parkinson's disease; PCA; Pre motor; SPT; Sucrose preference

Indexed keywords

2 BROMO N (2 CHLOROETHYL) N ETHYLBENZYLAMINE; DOPAMINE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; NEUROTOXIN; NEUROTRANSMITTER; NORADRENALIN; OXIDOPAMINE; PARACHLOROAMPETAMINE; SEROTONIN; SUCROSE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; FRONTAL CORTEX; IMMUNOHISTOCHEMISTRY; LOCUS CERULEUS; MALE; NERVE LESION; NEUROTRANSMISSION; NONHUMAN; NORADRENERGIC NERVE; PARKINSON DISEASE; PREMOTOR CORTEX; PRIORITY JOURNAL; RAT; SEROTONINERGIC NERVE CELL; SUBSTANTIA NIGRA;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; DOPAMINE; MALE; MOTOR ACTIVITY; NEURONS; NOREPINEPHRINE; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; PEPTIDES; RATS; RATS, WISTAR; RECOGNITION (PSYCHOLOGY); SEROTONIN; VENOMS;

ANIMALIA; RODENTIA;

EID: 84867040244     PISSN: 01434179     EISSN: 15322785     Source Type: Journal    
DOI: 10.1016/j.npep.2012.07.004     Document Type: Article

References (105)

1. Albin R.L., Koeppe R.A., Bohnen N.I., Wernette K., Kilbourn M.A., Frey K.A. Spared caudal brainstem SERT binding in early Parkinson's disease. J. Cereb. Blood Flow Metab. 2008, 28:441-444.
2. Arango V., Underwood M.D., Pauler D.K., Kass R.E., Mann J.J. Differential age-related loss of pigmented locus coeruleus neurons in suicides, alcoholics, and alcoholic suicides. Alcohol. Clin. Exp. Res. 1996, 20:1141-1147.
3. Archer T., Fredriksson A. Influence of noradrenaline denervation on MPTP-induced deficits in mice. J. Neural Transm. 2006, 113:1119-1129.
4. Bertilsson G., Patrone C., Zachrisson O., Andersson A., Dannaeus K., Heidrich J., Kortesmaa J., Mercer A., Nielsen E., Ronnholm H., Wikstrom L. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J. Neurosci. Res. 2008, 86:326-338.
5. Biggs C.S., Pearce B.R., Fowler L.J., Whitton P.S. Regional effects of sodium valproate on extracellular concentrations of 5-hydroxytryptamine, dopamine, and their metabolites in the rat brain: an in vivo microdialysis study. J. Neurochem. 1992, 59:1702-1708.
6. Borsini F., Volterra G., Meli A. Does the behavioral " despair" test measure " despair" ?. Physiol. Behav. 1986, 38:385-386.
7. Botton P.H., Costa M.S., Ardais A.P., Mioranzza S., Souza D.O., da Rocha J.B., Porciuncula L.O. Caffeine prevents disruption of memory consolidation in the inhibitory avoidance and novel object recognition tasks by scopolamine in adult mice. Behav. Brain Res. 2010, 214:254-259.
8. Bowenkamp K.E., David D., Lapchak P.L., Henry M.A., Granholm A.C., Hoffer B.J., Mahalik T.J. 6-hydroxydopamine induces the loss of the dopaminergic phenotype in substantia nigra neurons of the rat. A possible mechanism for restoration of the nigrostriatal circuit mediated by glial cell line-derived neurotrophic factor. Exp. Brain Res. 1996, 111:1-7.
9. Braak H., del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003, 24:197-211.
10. Branchi I., D'Andrea I., Armida M., Cassano T., Pezzola A., Potenza R.L., Morgese M.G., Popoli P., Alleva E. Nonmotor symptoms in Parkinson's disease: investigating early-phase onset of behavioral dysfunction in the 6-hydroxydopamine-lesioned rat model. J. Neurosci. Res. 2008, 86:2050-2061.
11. Burn D.J. Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson's disease. Mov. Disord. 2002, 17:445-454.
12. Buteau J., El-Assaad W., Rhodes C.J., Rosenberg L., Joly E., Prentki M. Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia 2004, 47:806-815.
13. Castren E., Thoenen H., Lindholm D. Brain-derived neurotrophic factor messenger RNA is expressed in the septum, hypothalamus and in adrenergic brain stem nuclei of adult rat brain and is increased by osmotic stimulation in the paraventricular nucleus. Neuroscience 1995, 64:71-80.
14. Chan-Palay V., Asan E. Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression. J. Comp. Neurol. 1989, 287:373-392.
15. Chaudhuri K.R., Healy D.G., Schapira A.H. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 2006, 5:235-245.
16. Chen X., Xu L., Radcliffe P., Sun B., Tank A.W. Activation of tyrosine hydroxylase mRNA translation by cAMP in midbrain dopaminergic neurons. Mol. Pharmacol. 2008, 73:1816-1828.
17. Cohen A.D., Zigmond M.J., Smith A.D. Effects of intrastriatal GDNF on the response of dopamine neurons to 6-hydroxydopamine: time course of protection and neurorestoration. Brain Res. 2011, 1370:80-88.
18. da Cunha C., Gevaerd M.S., Vital M.A., Miyoshi E., Andreatini R., Silveira R., Takahashi R.N., Canteras N.S. Memory disruption in rats with nigral lesions induced by MPTP: a model for early Parkinson's disease amnesia. Behav. Brain Res. 2001, 124:9-18.
19. da Cunha C., Wietzikoski S., Wietzikoski E.C., Silva M.H., Chandler J., Ferro M.M., Andreatini R., Canteras N.S. Pre-training to find a hidden platform in the Morris water maze can compensate for a deficit to find a cued platform in a rat model of Parkinson's disease. Neurobiol. Learn. Mem. 2007, 87:451-463.
20. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
21. Delaville C., Deurwaerdere P.D., Benazzouz A. Noradrenaline and Parkinson's disease. Front Syst. Neurosci. 2011, 5:31.
22. Du Y., Ma Z., Lin S., Dodel R.C., Gao F., Bales K.R., Triarhou L.C., Chernet E., Perry K.W., Nelson D.L., Luecke S., Phebus L.A., Bymaster F.P., Paul S.M. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci. U S A 2001, 98:14669-14674.
23. Dunkley P.R., Bobrovskaya L., Graham M.E., Von Nagy-Felsobuki E.I., Dickson P.W. Tyrosine hydroxylase phosphorylation: regulation and consequences. J. Neurochem. 2004, 91:1025-1043.
24. Ferro M.M., Bellissimo M.I., Anselmo-Franci J.A., Angellucci M.E., Canteras N.S., da Cunha C. Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations. J. Neurosci. Methods 2005, 148:78-87.
25. Filbin M.T. Myelin-associated inhibitors of axonal regeneration in the adult mammalian CNS. Nat. Rev. Neurosci. 2003, 4:703-713.
26. Fink J.S., Smith G.P. Mesolimbic and mesocortical dopaminergic neurons are necessary for normal exploratory behavior in rats. Neurosci. Lett. 1980, 17:61-65.
27. Foguet M., Hartikka J.A., Schmuck K., Lubbert H. Long-term regulation of serotonergic activity in the rat brain via activation of protein kinase A. EMBO J. 1993, 12:903-910.
28. Fornai F., Bassi L., Torracca M.T., Scalori V., Corsini G.U. Norepinephrine loss exacerbates methamphetamine-induced striatal dopamine depletion in mice. Eur. J. Pharmacol. 1995, 283:99-102.
29. Fornai F., Schluter O.M., Lenzi P., Gesi M., Ruffoli R., Ferrucci M., Lazzeri G., Busceti C.L., Pontarelli F., Battaglia G., Pellegrini A., Nicoletti F., Ruggieri S., Paparelli A., Sudhof T.C. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc. Natl. Acad. Sci. U S A 2005, 102:3413-3418.
30. Frisina P.G., Haroutunian V., Libow L.S. The neuropathological basis for depression in Parkinson's disease. Parkinsonism Relat. Disord. 2009, 15:144-148.
31. Gueorguiev V.D., Cheng S.Y., Sabban E.L. Prolonged activation of cAMP-response element-binding protein and ATF-2 needed for nicotine-triggered elevation of tyrosine hydroxylase gene transcription in PC12 cells. J. Biol. Chem. 2006, 281:10188-10195.
32. Guttman M., Boileau I., Warsh J., Saint-Cyr J.A., Ginovart N., McCluskey T., Houle S., Wilson A., Mundo E., Rusjan P., Meyer J., Kish S.J. Brain serotonin transporter binding in non-depressed patients with Parkinson's disease. Eur. J. Neurol. 2007, 14:523-528.
33. Harkavyi A., Abuirmeileh A., Lever R., Kingsbury A.E., Biggs C.S., Whitton P.S. Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. J. Neuroinflamm. 2008, 5:19.
34. Harkavyi A., Whitton P.S. Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection. Br. J. Pharmacol. 2010, 159:495-501.
35. Hirsch E., Graybiel A.M., Agid Y.A. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 1988, 334:345-348.
36. Iravani M.M., Leung C.C., Sadeghian M., Haddon C.O., Rose S., Jenner P. The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation. Eur. J. Neurosci. 2005, 22:317-330.
37. Isacson R., Nielsen E., Dannaeus K., Bertilsson G., Patrone C., Zachrisson O., Wikstrom L. The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test. Eur. J. Pharmacol. 2011, 650:249-255.
38. Ishihara L., Brayne C. A systematic review of depression and mental illness preceding Parkinson's disease. Acta Neurol. Scand. 2006, 113:211-220.
39. Jardanhazi-Kurutz D., Kummer M.P., Terwel D., Vogel K., Dyrks T., Thiele A., Heneka M.T. Induced LC degeneration in APP/PS1 transgenic mice accelerates early cerebral amyloidosis and cognitive deficits. Neurochem. Int. 2010, 57:375-382.
40. Jellinger K.A. Post mortem studies in Parkinson's disease - is it possible to detect brain areas for specific symptoms?. J. Neural Transm. Suppl. 1999, 56:1-29.
41. Jenkins T.A., Elliott J.J., Ardis T.C., Cahir M., Reynolds G.P., Bell R., Cooper S.J. Tryptophan depletion impairs object-recognition memory in the rat: reversal by risperidone. Behav. Brain Res. 2010, 208:479-483.
42. Kerenyi L., Ricaurte G.A., Schretlen D.J., McCann U., Varga J., Mathews W.B., Ravert H.T., Dannals R.F., Hilton J., Wong D.F., Szabo Z. Positron emission tomography of striatal serotonin transporters in Parkinson disease. Arch. Neurol. 2003, 60:1223-1229.
43. Kim S., Moon M., Park S. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease. J. Endocrinol. 2009, 202:431-439.
44. Kim S.Y., Lee Y.J., Kim H., Lee D.W., Woo D.C., Choi C.B., Chae J.H., Choe B.Y. Desipramine attenuates forced swim test-induced behavioral and neurochemical alterations in mice. an in vivo(1)H-MRS study at 9.4T. Brain Res. 2010, 1348:105-113.
45. Kish S.J. Biochemistry of Parkinson's disease: is a brain serotonergic deficiency a characteristic of idiopathic Parkinson's disease?. Adv. Neurol. 2003, 91:39-49.
46. Klimek V., Stockmeier C., Overholser J., Meltzer H.Y., Kalka S., Dilley G., Ordway G.A. Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. J. Neurosci. 1997, 17:8451-8458.
47. Kornum B.R., Licht C.L., Weikop P., Knudsen G.M., Aznar S. Central serotonin depletion affects rat brain areas differently: a qualitative and quantitative comparison between different treatment schemes. Neurosci. Lett. 2006, 392:129-134.
48. Lategan A.J., Marien M.R., Colpaert F.C. Effects of locus coeruleus lesions on the release of endogenous dopamine in the rat nucleus accumbens and caudate nucleus as determined by intracerebral microdialysis. Brain Res. 1990, 523:134-138.
49. Ledoux J.E. Emotion circuits in the brain. Annu. Rev. Neurosci. 2000, 23:155-184.
50. Lee S., Jeong J., Kwak Y., Park S.K. Depression research: where are we now?. Mol Brain 2010, 3:8.
51. Leentjens A.F., Vreeling F.W., Luijckx G.J., Verhey F.R. SSRIs in the treatment of depression in Parkinson's disease. Int. J. Geriatr. Psychiatry 2003, 18:552-554.
52. Lees A.J., Hardy J., Revesz T. Parkinson's disease. Lancet 2009, 373:2055-2066.
53. Lees A.J., Smith E. Cognitive deficits in the early stages of Parkinson's disease. Brain 1983, 106(Pt 2):257-270.
54. Leonard B.E. Acute and chronic effects of 4-chloroamphetamine on monoamine metabolism in the rat brain. Psychopharmacologia 1976, 46:11-18.
55. Li Y., Chigurupati S., Holloway H.W., Mughal M., Tweedie D., Bruestle D.A., Mattson M.P., Wang Y., Harvey B.K., Ray B., Lahiri D.K., Greig N.H. Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis. PLoS ONE 2012, 7:e32008.
56. Li Y., Hansotia T., Yusta B., Ris F., Halban P.A., Drucker D.J. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J. Biol. Chem. 2003, 278:471-478.
57. Li Y., Tweedie D., Mattson M.P., Holloway H.W., Greig N.H. Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells. J. Neurochem. 2010, 113:1621-1631.
58. Lieben C.K., van Oorsouw K., Deutz N.E., Blokland A. Acute tryptophan depletion induced by a gelatin-based mixture impairs object memory but not affective behavior and spatial learning in the rat. Behav. Brain Res. 2004, 151:53-64.
59. Lieberman A. Depression in Parkinson's disease - a review. Acta Neurol. Scand. 2006, 113:1-8.
60. Marie R.M., Barre L., Rioux P., Allain P., Lechevalier B., Baron J.C. PET imaging of neocortical monoaminergic terminals in Parkinson's disease. J. Neural Transm. Park Dis. Dement. Sect. 1995, 9:55-71.
61. Martin B., Golden E., Carlson O.D., Pistell P., Zhou J., Kim W., Frank B.P., Thomas S., Chadwick W.A., Greig N.H., Bates G.P., Sathasivam K., Bernier M., Maudsley S., Mattson M.P., Egan J.M. Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease. Diabetes 2009, 58:318-328.
62. Mavridis M., Degryse A.D., Lategan A.J., Marien M.R., Colpaert F.C. Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease. Neuroscience 1991, 41:507-523.
63. Mayberg H.S. Frontal lobe dysfunction in secondary depression. J. Neuropsychiatry Clin. Neurosci. 1994, 6:428-442.
64. Mayberg H.S., Solomon D.H. Depression in Parkinson's disease: a biochemical and organic viewpoint. Adv. Neurol. 1995, 65:49-60.
65. Mayeux R. Depression in the patient with Parkinson's disease. J. Clin. Psychiatry 1990, 51(Suppl.):20-23. (discussion 24-5).
66. Merchenthaler I., Lane M., Shughrue P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J. Comp. Neurol. 1999, 403:261-280.
67. Na S.J., Dilella A.G., Lis E.V., Jones K., Levine D.M., Stone D.J., Hess J.F. Molecular profiling of a 6-hydroxydopamine model of Parkinson's disease. Neurochem. Res. 2010, 35:761-772.
68. Nilsson F.M., Kessing L.V., Bolwig T.G. Increased risk of developing Parkinson's disease for patients with major affective disorder: a register study. Acta Psychiatr. Scand. 2001, 104:380-386.
69. Nishimura H., Tsuda A., Oguchi M., Ida Y., Tanaka M. Is immobility of rats in the forced swim test " behavioral despair" ?. Physiol. Behav. 1988, 42:93-95.
70. O'Meara G., Coumis U., Ma S.Y., Kehr J., Mahoney S., Bacon A., Allen S.J., Holmes F., Kahl U., Wang F.H., Kearns I.R., Ove-Ogren S., Dawbarn D., Mufson E.J., Davies C., Dawson G., Wynick D. Galanin regulates the postnatal survival of a subset of basal forebrain cholinergic neurons. Proc. Natl. Acad. Sci. U S A 2000, 97:11569-11574.
71. Olanow C.W., Tatton W.G. Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci. 1999, 22:123-144.
72. Owen A.M. Cognitive dysfunction in Parkinson's disease: the role of frontostriatal circuitry. Neuroscientist 2004, 10:525-537.
73. Packard M.G., Knowlton B.J. Learning and memory functions of the Basal Ganglia. Annu. Rev. Neurosci. 2002, 25:563-593.
74. Park A., Stacy M. Non-motor symptoms in Parkinson's disease. J. Neurol. 2009, 256(Suppl 3):293-298.
75. Perry T., Haughey N.J., Mattson M.P., Egan J.M., Greig N.H. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J. Pharmacol. Exp. Ther. 2002, 302:881-888.
76. Perry T., Lahiri D.K., Chen D., Zhou J., Shaw K.T., Egan J.M., Greig N.H. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J. Pharmacol. Exp. Ther. 2002, 300:958-966.
77. Perry T.A., Greig N.H. A new Alzheimer's disease interventive strategy: GLP-1. Curr. Drug Targets 2004, 5:565-571.
78. Politis M., Loane C. Serotonergic dysfunction in Parkinson's disease and its relevance to disability. ScientificWorldJournal 2011, 11:1726-1734.
79. Politis M., Wu K., Loane C., Kiferle L., Molloy S., Brooks D.J., Piccini P. Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study. Neurobiol. Dis. 2010, 40:216-221.
80. Porsolt R.D., Anton G., Blavet N., Jalfre M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur. J. Pharmacol. 1978, 47:379-391.
81. Reksidler A.B., Lima M.M., Zanata S.M., Machado H.B., da Cunha C., Andreatini R., Tufik S., Vital M.A. The COX-2 inhibitor parecoxib produces neuroprotective effects in MPTP-lesioned rats. Eur. J. Pharmacol. 2007, 560:163-175.
82. Remy P., Doder M., Lees A., Turjanski N., Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005, 128:1314-1322.
83. Ressler K.J., Nemeroff C.B. Role of norepinephrine in the pathophysiology and treatment of mood disorders. Biol. Psychiatry 1999, 46:1219-1233.
84. Rommelfanger K.S., Weinshenker D. Norepinephrine: The redheaded stepchild of Parkinson's disease. Biochem. Pharmacol. 2007, 74:177-190.
85. Roozendaal B., Castello N.A., Vedana G., Barsegyan A., McGaugh J.L. Noradrenergic activation of the basolateral amygdala modulates consolidation of object recognition memory. Neurobiol. Learn. Mem. 2008, 90:576-579.
86. Ross S.B. Long-term effects of N-2-chlorethyl-N-ethyl-2-bromobenzylamine hydrochloride on noradrenergic neurones in the rat brain and heart. Br. J. Pharmacol. 1976, 58:521-527.
87. Saint-Cyr J.A., Taylor A.E., Lang A.E. Procedural learning and neostriatal dysfunction in man. Brain 1988, 111(Pt 4):941-959.
88. Santiago R.M., Barbieiro J., Lima M.M., Dombrowski P.A., Andreatini R., Vital M.A. Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34:1104-1114.
89. Sauer H., Oertel W.H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 1994, 59:401-415.
90. Schmidt H.D., Duman R.S. Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models. Neuropsychopharmacology 2010, 35:2378-2391.
91. Schuurman A.G., van den Akker M., Ensinck K.T., Metsemakers J.F., Knottnerus J.A., Leentjens A.F., Buntinx F. Increased risk of Parkinson's disease after depression: a retrospective cohort study. Neurology 2002, 58:1501-1504.
92. Shimohama S., Sawada H., Kitamura Y., Taniguchi T. Disease model: Parkinson's disease. Trends Mol. Med. 2003, 9:360-365.
93. Spiegel J., Storch A., Jost W.H. Early diagnosis of Parkinson's disease. J. Neurol. 2006, 253(Suppl. 4):IV2-IV7.
94. Srinivasan J., Schmidt W.J. Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats. Eur. J. Neurosci. 2003, 17:2586-2592.
95. Sy H.N., Wu S.L., Wang W.F., Chen C.H., Huang Y.T., Liou Y.M., Chiou C.S., Pawlak C.R., Ho Y.J. MPTP-induced dopaminergic degeneration and deficits in object recognition in rats are accompanied by neuroinflammation in the hippocampus. Pharmacol. Biochem. Behav. 2010, 95:158-165.
96. Tadaiesky M.T., Dombrowski P.A., Figueiredo C.P., Cargnin-Ferreira E., da Cunha C., Takahashi R.N. Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease. Neuroscience 2008, 156:830-840.
97. Taylor T.N., Caudle W.M., Shepherd K.R., Noorian A., Jackson C.R., Iuvone P.M., Weinshenker D., Greene J.G., Miller G.W. Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity. J. Neurosci. 2009, 29:8103-8113.
98. Tolosa E., Compta Y., Gaig C. The premotor phase of Parkinson's disease. Parkinsonism Relat. Disord. 2007, 13(Suppl.):S2-S7.
99. Torriero S., Oliveri M., Koch G., Lo Gerfo E., Salerno S., Petrosini L., Caltagirone C. Cortical networks of procedural learning: evidence from cerebellar damage. Neuropsychologia 2007, 45:1208-1214.
100. Wang Y., Zhang Q.J., Liu J., Ali U., Gui Z.H., Hui Y.P., Chen L., Wu Z.H., Li Q. Noradrenergic lesion of the locus coeruleus increases apomorphine-induced circling behavior and the firing activity of substantia nigra pars reticulata neurons in a rat model of Parkinson's disease. Brain Res. 2010, 1310:189-199.
101. Weintraub D., Comella C.L., Horn S. Parkinson's disease-Part 3: Neuropsychiatric symptoms. Am. J. Manag. Care 2008, 14:S59-S69.
102. Winter C., von Rumohr A., Mundt A., Petrus D., Klein J., Lee T., Morgenstern R., Kupsch A., Juckel G. Lesions of dopaminergic neurons in the substantia nigra pars compacta and in the ventral tegmental area enhance depressive-like behavior in rats. Behav. Brain Res. 2007, 184:133-141.
103. Wong F.K., Lee S.H., Atcha Z., Ong A.B., Pemberton D.J., Chen W.S. Rasagiline improves learning and memory in young healthy rats. Behav. Pharmacol. 2010, 21:278-282.
104. Yamamoto H., Kishi T., Lee C.E., Choi B.J., Fang H., Hollenberg A.N., Drucker D.J., Elmquist J.K. Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J. Neurosci. 2003, 23:2939-2946.
105. Ziemssen T., Reichmann H. Non-motor dysfunction in Parkinson's disease. Parkinsonism Relat. Disord. 2007, 13:323-332.